Tarsus Pharmaceuticals, Inc.

The company is a commercial-stage biopharmaceutical business focused on developing and commercializing therapeutics, primarily targeting eye care and infectious disease prevention. Its primary commercial product is XDEMVY, an FDA-approved prescription ophthalmic solution that treats Demodex blepharitis by eradicating Demodex mites through GABA-Cl channel inhibition. Additionally, the business develops investigational formulations using the lotilaner active pharmaceutical ingredient, including a topical gel candidate for ocular rosacea and an oral tablet candidate designed for Lyme disease prophylaxis. Its commercialized offerings serve patients presenting with mite infestations and ocular conditions, prescribed directly by eye care professionals such as ophthalmologists and optometrists.

Commercial operations are primarily focused in the United States, where XDEMVY is actively marketed and sold via a dedicated specialty sales force. Beyond its core domestic presence, international expansion efforts include licensing partnerships in Greater China, alongside development and regulatory pursuits targeting approval in Europe and Japan. The provided text does not disclose the location of the company's headquarters or its founding year.

Summary of the business section of Tarsus Pharmaceuticals's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of December 31, 2025, we had 370 full-time employees.”